ERYTECH announces positive safety review for eryaspase in its Phase 2 study in pancreatic cancer Post author:admERY Post published:July 20, 2015 Post category:Newsroom ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer. You Might Also Like General Meeting to be held on June 28, 2018 and Availability of Related Materials June 7, 2018 ERYTECH completes enrollment in its Phase III study in Acute Lymphoblastic Leukemia September 10, 2013 ERYTECH to Webcast Presentation at Jefferies 2017 London Healthcare Conference November 14, 2017
ERYTECH completes enrollment in its Phase III study in Acute Lymphoblastic Leukemia September 10, 2013